Filing summary
Registrant and period: This is Cortexyme, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, filed November 12, 2020. The request metadata names Quince Therapeutics, but the supplied filing is for Cortexyme (Nasdaq: CRTX).
Business context and financial results
Cortexyme is a clinical-stage biopharmaceutical company developing atuzaginstat (COR388), an investigational treatment for Alzheimer’s disease. It reported no product revenue and continued to incur operating losses.
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Research and development expense | $17.0 million | $8.3 million | $45.5 million | $20.2 million |
| General and administrative expense | $4.9 million | $2.3 million | $12.6 million | $6.0 million |
| Total operating expenses | $21.9 million | $10.6 million | $58.0 million | $26.2 million |
| Net loss | $21.5 million | $9.9 million | $56.3 million | $24.6 million |
| Basic and diluted loss per share | $0.73 | $0.37 | $1.94 | $1.59 |
For the nine-month period, operating cash use was $37.5 million; investing cash use was $68.3 million, principally reflecting purchases of investments net of maturities; and financing provided $118.8 million, largely from the February 2020 private placement. Cash and cash equivalents at September 30 were $64.2 million. Short-term investments were $73.5 million and long-term investments $60.1 million, for total cash, cash equivalents and investments of approximately $197.9 million. The filing reports no borrowings; liabilities included $0.5 million of operating lease liabilities, as well as ordinary payables and accruals.
Margins are not meaningful because the company had no product revenue. Accumulated deficit was $126.1 million. Stock-based compensation was $9.5 million for the first nine months of 2020, versus $1.5 million in the prior-year period.
Material changes versus prior comparable periods
- Nine-month net loss increased by $31.7 million year over year, while operating expenses more than doubled. Management attributed the R&D increase mainly to GAIN trial activity, patient enrollment, drug manufacturing, and increased personnel costs.
- Q3 R&D increased $8.7 million year over year; G&A rose $2.6 million, including higher personnel and stock-based compensation expenses and public-company costs.
- In February 2020, Cortexyme raised $125.0 million gross through a private placement of 2.5 million shares at $50 per share, receiving $117.6 million net. Shares outstanding at September 30 were 29.5 million, compared with 26.9 million at December 31, 2019.
- Interest income for Q3 fell to $0.4 million from $0.7 million, which management attributed to lower portfolio yields. Nine-month interest income rose slightly to $1.7 million from $1.6 million, reflecting higher average invested balances offset by lower yields.
Outlook, commentary and risks
- Management stated that cash, cash equivalents and short-term investments were expected to fund planned operations for at least one year from the filing, and separately said existing capital resources were expected to fund operations through 2022, including completion and announcement of GAIN topline results. These are management estimates, not assurances.
- The global Phase 2/3 GAIN trial evaluates atuzaginstat in mild-to-moderate Alzheimer’s disease. Management planned an interim analysis by the end of 2020 after approximately 100 participants in each of three arms completed 24 weeks of treatment, with topline results expected by the end of 2021. Final enrollment was reported as 643 participants in November 2020.
- The U.S. open-label extension began dosing in April 2020 and is intended to assess longer-term safety and efficacy. The filing said COVID-19 had not, at that time, changed stated analysis timelines; the company had drug supply on hand for the GAIN trial and reported no significant supply-chain disruption to date. Further pandemic effects on trials, suppliers, operations and timelines remained uncertain.
- The FDA had imposed a partial clinical hold to limit exposure because of toxicity observed at very high exposure levels in mice. The filing says planned GAIN doses were permitted, but a need to increase human doses could be constrained by the hold.
- Key risks include clinical efficacy and safety uncertainty, regulatory review, trial execution and enrollment, manufacturing and vendor dependence, COVID-19 disruption, and the possibility of needing additional capital. The company cautioned that further financing may dilute shareholders or require unfavorable terms. It reported no material legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the filing’s issuer: the supplied 10-Q is Cortexyme, Inc., not Quince Therapeutics.
- Check subsequent GAIN interim and topline results, trial status, and any changes to expected timing or enrollment.
- Review later disclosures on the FDA partial clinical hold, safety findings, and whether dose limitations affect development.
- Track cash and investment balances, operating cash burn, and whether management’s stated runway assumptions remain current.
- Assess the effect of rising R&D spending, stock-based compensation, and any future equity or debt financing on shareholder dilution.